Insulin lispro U100 is under clinical development by Adocia and currently in Phase II for Type 1 Diabetes (Juvenile Diabetes). According to GlobalData, Phase II drugs for Type 1 Diabetes (Juvenile Diabetes) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Insulin lispro U100’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Insulin lispro U100 overview
Insulin lispro is under development for the treatment of type 1 and type 2 diabetes. The drug candidate is administered subcutaneously. The drug candidate is a new biological entity (NBE). Ultra-fast acting biochaperone-insulin analog is a prandial insulin which acts more rapidly than the current insulin analogs providing better glycemic control.
Adocia is a biotechnology company, which carries out the development of therapeutic proteins and peptides. The company’s clinical pipeline product offerings include Biochaperone Lispro insulin, Biochaperone Combo for type-2 diabetes, M1Pram for type-1 diabetes, Biochaperone Glucagon for hyperglycemia, Biochaperone GLA GLP-1 basal insulin and Biochaperone Glucagon GLP-1 for Obesity. Its BioChaperone is a proprietary technology platform developed from polymers, oligomers and small organic compounds, protects proteins from enzymatic degradation and enhances performance. The company also provides preclinical stage cell therapy concentrating on the development of a hydrogel scaffold for people diagnosed with type 1 diabetes. Adocia is headquartered in Lyon, Auvergne-Rhone-Alpes, France.
For a complete picture of Insulin lispro U100’s drug-specific PTSR and LoA scores, buy the report here.